- Home
- Automated
- NDF A-Z listing
- Empagliflozin
E
Empagliflozin
Subsidy Information and Financing Scheme
SDL
Drug Guidance
Yes
Post-marketing information
Yes
Summary of Biologics
No
Active ingredient: Empagliflozin
General information
Subsidy Information and Financing Scheme
[SDL] Empagliflozin Tablet 10 mg, 25 mg
Legend
This section shows the following:
Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs
Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List
Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List
As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.
Legend list
Indicator | Legend |
|---|---|
SDL | Standard Drug List |
MAF | Medical Assistance Fund |
SVL | Subsidised Vaccine List |
MSHL | Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List |
Drug Guidance for Subsidy
02/01/2024 SGLT2 inhibitors for treating heart failure and chronic kidney disease
The Ministry of Health’s Drug Advisory Committee has recommended:
Empagliflozin 10 mg and 25 mg tablets
in line with its registered indications for treating heart failure and chronic kidney disease, in view of favourable clinical and cost-effectiveness.
Funding status
[R] Empagliflozin 10 mg and 25 mg tablets are recommended for inclusion on the Standard Drug List (SDL) from 1 November 2023.
[NR] Of note, dapagliflozin 5 mg and 10 mg tablets will be delisted from the MOH List of Subsidised Drugs with effect from 1 August 2024 due to unfavourable cost-effectiveness compared with empagliflozin.
02/01/2024 Sodium-glucose co-transporter 2 (SGLT2) inhibitors for treating type 2 diabetes mellitus
The Ministry of Health’s Drug Advisory Committee has recommended:
Empagliflozin 10 mg and 25 mg tablets
in line with its registered indication for treating type 2 diabetes mellitus, in view of favourable clinical and cost-effectiveness.
Funding status
[R] Empagliflozin 10 mg and 25 mg tablets are recommended for inclusion on the Standard Drug List (SDL) from 1 November 2023.
[NR] Of note, dapagliflozin 5 mg and 10 mg tablets will be delisted from the MOH List of Subsidised Drugs with effect from 1 August 2024 due to unfavourable cost-effectiveness compared with empagliflozin. Subsidy does not apply to any formulations or strengths of canagliflozin.
Legend
This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.
Legend list
Indicator | Legend |
|---|---|
R | Recommended for subsidy |
NR | Not recommended for subsidy |
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Drug availability
Formulation | Public Healthcare Institution |
|---|---|
Tablet 10 mg |
|
Tablet 25 mg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |